Type 1 Diabetes Fellows Series

February 01, 2024

Application Period Is Now Closed

The application for the 11th annual installment of Endocrine Society’s Type 1 Diabetes Fellows series is now closed. Applicants will receive notifications and more details by no later than mid-March. Fellows that are invited to attend the in-person meeting will receive a promotional code for complimentary registration to ENDO 2024, as well as a travel stipend. To avoid any issues, we kindly request that applicants refrain from registering for the conference until after they have heard back about their application. Non-accepted applicants will be provided a promo code. 

Have questions? Please contact education@endocrine.org for assistance. 

As in years past, the Type 1 Diabetes Fellows Program will have two core components:  

  • On-demand didactic sessions; and 
  • A prestigious, in-person meeting held in Boston, MA, May 30-31, ahead of ENDO, where fellows get the exclusive opportunity to meet with experts in T1D and product demonstrations with industry representatives.  

Travel Visas

All individuals traveling from outside the United States must apply for entry visas as soon as possible and at least four months prior to the date of travel for ENDO 2024. The most updated information may be found at the U.S. State Department website. Scientists visiting the U.S. may find helpful information at The National Academies of Sciences website. Visa appointment wait times can be found here.  

Please do not wait until to hear about your application or until ENDO 2024 registration opens in January 2024 before applying for a visa. All visitors traveling to the U.S. from visa waiver countries (i.e., Europe, Japan, Australia, etc.) must meet all requirements. If you need more information on the Electronic System for Travel Authorization (ESTA) or a list of visa waiver countries, click here. For information on the anticipated timeline, please visit the State Department website. 

Please contact meetings@endocrine.org to request a visa invitation letter. 

Past Program Highlights (2023):

Gain insights into the enriching experience participants had in our last year's workshop. Explore the agenda, topics covered, and the valuable takeaways from the Summer 2023 program. This will give you a glimpse of what to expect in our upcoming workshop in June 2024. 

2023 Program Agenda

Tuesday, June 13, 2023

 6:00-6:30 PM            

 Welcome Reception 

 6:30-7:00 PM

 Dinner

 7:00-7:45 PM

 Keynote Address: Cheating Destiny: Living with Diabetes, America's Biggest Epidemic
James S. Hirsch 

 7:45-8:00 PM

 Q&A

 8:00-9:00 PM

 Product Showcase


Wednesday, June 14, 2023

7:00-8:00 AM             

Registration and Breakfast with the Faculty 

 8:00-8:10 AM

Welcoming Remarks
Irl B. Hirsch, MD, University of Washington
Davida F. Kruger, MSN, APN-BC, BC-ADM, Henry Ford Health

 8:10-8:50 AM

Closing the Loop with Diabetes Technology
CGM Use and Interpretation with MDI

Viral Shah, MD, University of Colorado

 8:50-9:30 AM

Closing the Loop with Diabetes Technology
CGM Use and Interpretation with Open Loop

Anne Peters, MD, USC Westside Center for Diabetes 

 9:30-10:10 AM

Closing the Loop with Diabetes Technology 
CGM Use and Interpretation with Closed Loop

Irl B. Hirsch, MD, University of Washington  

 10:10-10:40 AM

Break & Questions for Industry Representatives 

 10:40-11:55 AM

Small Group Discussions

Sick Day
Faisal S. Malik, MD, MSHS, Seattle Children’s Hospital

In-Patient Management
Alexis McKee, MD, CDCES, Washington University School of Medicine in St. Louis

T1D in Underserved Populations
Lorena Wright, MD, FACE, University of Washington

Implementing Realistic Nutrition Therapy for People with Type 1 Diabetes
Patti Urbanski, MEd, RD, LD, CDE, St. Luke's Duluth

Exercise Management: Considerations and Strategies for T1D
Michael C. Riddell, PhD, York University

Tidepool Loop and Expanding Closed Loop Access
Howard Look, Tidepool 

 11:55 AM-12:55 PM  

Lunch Discussion with Faculty

 12:55-1:35 PM

Biostatistics for the Clinical Endocrinologist  
Roy W. Beck, MD, PhD, Jaeb Center for Health Research 

 1:35-2:15 PM

Novel Immune Therapy
Carla J. Greenbaum, MD, Benaroya Research Institute 

 2:15-2:45 PM

Break & Questions for Industry Representatives

 2:45-4:00 PM

Small Group Discussion:

Identifying and Confronting Challenging Transitions
Faisal S. Malik, MD, MSHS, Seattle Children’s Hospital

In-Patient Management
Alexis McKee, MD, CDCES, Washington University School of Medicine in St. Louis

T1D in Underserved Populations
Lorena Wright, MD, FACE, University of Washington

Implementing Realistic Nutrition Therapy for People with Type 1 Diabetes
Patti Urbanski, MEd, RD, LD, CDE, St. Luke's Duluth

Exercise Management: Considerations and Strategies for T1D
Michael C. Riddell, PhD, York University

Tidepool Loop and Expanding Closed Loop Access
Howard Look, Tidepool

 4:00-4:40 PM

Fresh Look at Insulin  
Dr. Bernard Zinman, FRCP, FACP, MD, Mount Sinai Hosp, University of Toronto 

 4:40-5:00 PM

Closing Comments
Irl B. Hirsch, MD, University of Washington
Davida F. Kruger, MSN, APN-BC, BC-ADM, Henry Ford Health 

 

 


On-Demand Program (45-min sessions)

  • Newly Diagnosed of Type 1 Diabetes: Irl B. Hirsch, MD, University of Washington
  • Hypoglycemia in T1D: Risks and Practical Prevention Strategies - Elizabeth Seaquist, MD, University of Minnesota
  • Phases of Diabetes - Carla J. Greenbaum, MD, Benaroya Research Institute
  • T1D and the Prevention and Treatment of Macrovascular Disease - Robert H. Eckel, MD, University of Colorado
  • The Endocrinologist’s Role in Screening/Managing Microvascular Disease - Janet McGill, MD, MA, FACE, Washington University in St. Louis
  • Identifying and Confronting Challenging Transitions - Faisal S. Malik, MD, MSHS, Seattle Children’s Hospital
  • Developmental Perspectives in the Psychosocial Aspects of Diabetes - Jill A. Weissberg-Benchell, PhD, CDE, Northwestern University
  • Pathogenesis of T1D: The Future for Preserving Beta Cell Function – Todd Brusko, MD, University of Florida
  • Type 1 Diabetes in Pregnancy: Before, During, and After - Camille Powe, MD, Massachusetts General Hospital
  • Applying New Billing Rules to Outpatient Diabetes Care – Carol Wysham, MD, Rockwood Clinic
  • Preparing for Future Careers in Endocrinology: What I Wish I was Told When I Left My Fellowship – Luisa Duran, MD, John Muir Health
  • Obesity and Type 1 Diabetes – Eden M. Miller, DO, Diabetes and Obesity Care
  • Adjunctive Therapies for T1D – Anne Peters, MD, USC Westside Center for Diabetes 

Learning Objectives

Upon successful completion these educational initiatives, participants should be better able to:

  • Discuss the prevalence and progression of type 1 diabetes to recognize signs and differentially diagnose diabetes
  • Devise individualized treatment strategies that use new and emerging insulin therapies to manage individuals with type 1 diabetes with and without common comorbid conditions.
  • Incorporate diabetes technologies, including insulin pump therapy and continuous glucose monitoring, into treatment strategies for appropriate individuals with type 1 diabetes and evaluate data from those technologies.
  • Recognize and evaluate individuals with type 1 diabetes for signs of depression and distress using updated guidelines and practice tools.
  • Apply updated knowledge of treatments, practice guidelines, and clinical skills to improve care, long-term outcomes, and sick day management of individuals with type 1 diabetes.
  • Describe current and emerging therapy for the treatment of pre-clinical type 1 diabetes
  • Discuss various strategies for exercise and minimizing hypoglycemia for individuals with T1D
Last Updated:
Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.